One Nucleus: Dr. Michael Wyand to participate in panel

Written By Lindsey McClelland

Oxeia Biopharmaceuticals CEO, Dr. Michael Wyand, is participating in One Nucleus BioWednesday Webinar on concussions on Wednesday, July 14, 2021 from 11:00 am to noon Eastern Daylight Time: Prevention vs. Cure – If you can’t remove all risk can you at least treat the outcome? Panelists will discuss current R&D for concussion treatment, new technologies for diagnosing and monitoring concussions and the case for investing in new drugs to treat concussions.

Lindsey McClelland
Previous

Oxeia CEO Michael Wyand participated in OneNucleus BioWednesday Webinar: Prevention vs. Cure
Next

Roll Call: Concussions and First Responders